Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Tongji Hospital
Tongji Hospital
Kivu Bioscience Inc.
University of California, San Francisco
M.D. Anderson Cancer Center
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Edwards Lifesciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
7 Hills Pharma, LLC
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Beijing Biotech
Parabilis Medicines, Inc.
The Methodist Hospital Research Institute
Revolution Medicines, Inc.
Centre Leon Berard
Pfizer
Pfizer
USWM, LLC (dba US WorldMeds)
Coherus Oncology, Inc.
Lumos Pharma
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
Taiho Oncology, Inc.
Alterome Therapeutics, Inc.
Verastem, Inc.
IDEAYA Biosciences
M.D. Anderson Cancer Center
Shanghai 10th People's Hospital
Aulos Bioscience, Inc.
Buzzard Pharmaceuticals
HonorHealth Research Institute
iOnctura
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
UMC Utrecht
Boston Scientific Corporation